Gilead Sciences shares declined 1.38% in the latest trading session, underperforming the broader market. The move came despite the company’s steady fundamentals, and followed a period during which the 50-day moving average sat modestly above the 200-day average, reflecting a medium‐term uptrend in place prior to today’s pullback.

Abacus FCF Advisors LLC reduced its stake in Gilead by 16.0%, offloading 26,340 shares and retaining 138,674 shares valued at $15.39 million as of the quarter’s end. Norges Bank initiated a new position of approximately $2.15 billion in the second quarter. Ameriprise Financial expanded its holding by 397.6%, adding 5.39 million shares and bringing its total to 6.75 million shares. Invesco lifted its stake by 33.5%, acquiring 3.39 million additional shares. Assenagon Asset Management increased its position by 164.4%, purchasing 2.17 million shares, and Kingstone Capital Partners Texas entered with a new $238.08 million commitment. Institutional investors now account for roughly 83.7% of the float.

Director Johanna Mercier sold 3,000 shares, reducing her position by 2.75% and generating $366,000 in proceeds, while Director Jeffrey Bluestone sold 5,000 shares—a 35.9% reduction—yielding $625,400. Over the past 90 days, insiders have sold a total of 126,257 shares, representing 0.27% of outstanding stock.

In the third quarter, Gilead posted revenue of $7.77 billion, up 3.0% year-over-year, and delivered earnings per share of $2.47, beating consensus by $0.31. Net margin stood at 27.9% and return on equity at 51.9%. The company set full-year EPS guidance at a range of 8.05–8.25, with analysts forecasting 7.95 for the year. A quarterly dividend of $0.79 was declared, representing a 2.5% yield and a payout ratio near 49%.